Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial.
Okugawa S, Ikeda M, Kashiwabara K, Moritoyo T, Kohsaka T, Shimizu T, Hagiya H, Hasegawa K, Otsuka F, Miwa A, Kisimoto N, Mizoguchi A, Imamura A, Ikeuchi K, Tsutsumi T, Jubishi D, Hashimoto H, Okamoto K, Harada S, Inoue JI, Seto Y, Moriya K.
Okugawa S, et al. Among authors: ikeuchi k.
Int J Antimicrob Agents. 2023 Sep;62(3):106922. doi: 10.1016/j.ijantimicag.2023.106922. Epub 2023 Jul 8.
Int J Antimicrob Agents. 2023.
PMID: 37429450
Free article.
Clinical Trial.